2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176052
    PPO-allene 98%
    PPO-allene is a covalent botulinum neurotoxin (BoNT) light chain inhibitor (IC50: 20.9 μM). PPO-allene (0.3 mg/kg, i.v.) demonstrates an in vivo half-life of approximately 1.5 h in mice.
    PPO-allene
  • HY-176063
    TRPV1 antagonist 11 98%
    TRPV1 antagonist 11 (compound 2ac) is a potent TRPV1 antagonist with an IC50 of 29.3 nM. TRPV1 antagonist 11 is a potent μ-opioid receptor (MOR) agonist with a Ki of 60.3 nM. TRPV1 antagonist 11, a pyrimidine piperazine, exhibits pain relieving effects by antagonizing TRPV1 and stimulating MOR. TRPV1 antagonist 11 shows a potent, dose-dependent anti-nociceptive effect in a Formalin-induced pain model in mice.
    TRPV1 antagonist 11
  • HY-176065
    Nav1.2-IN-1 98%
    Nav1.2-IN-1 (compound 5i), a 3-(1,2,3,6-tetrahydropyridine)-4-azaindole derivative, is a potent and selective Nav1.2 inhibitor. Nav1.2-IN-1 induces a reduction in the peak amplitude of Nav1.2 currents with an IC50 value of 7.79 μM. Nav1.2-IN-1 exhibits antiepileptic activity. Nav1.2-IN-1 shows high anticonvulsant effect and low neurotoxicity in subcutaneous Pentetrazole (sc-PTZ)-induced epilepsy mode.
    Nav1.2-IN-1
  • HY-176122
    VU6024945 98%
    VU6024945 is an orally active negative allosteric modulator of metabotropic glutamate receptor subtype 5 (mGlu5 NAM) with an IC50 value of 110 nM. VU6024945 can be used in the research of anti-anxiety, anti-depression and Parkinson's disease and other neurological diseases.
    VU6024945
  • HY-17612A
    Evenamide hydrochloride 1092977-06-4 98%
    Evenamide hydrochloride is an orally available voltage-gated sodium channel (VGSC) blocker (Ki=0.4 μM) for the research of schizophrenia. Evenamide hydrochloride shows efficacy in a broad spectrum of rodent models of psychosis, mania, depression, and aggressiveness.
    Evenamide hydrochloride
  • HY-176130
    MRL828 98%
    MRL828 combines a Tau pathology-binding ligand and modified guanine moiety based on the ATTEC technology to selectively designate aggregated tau proteins for clearance via the ALP. MRL828 decreases intracellular Tau aggregates and promotes the secretion of Tau.
    MRL828
  • HY-176132
    BI 1181181 MZ 98%
    BI 1181181 MZ is a potent and selective BACE1 inhibitor. BI 1181181 MZ can be used in the research for Alzheimer’s disease.
    BI 1181181 MZ
  • HY-176141
    ZH8965 98%
    ZH8965 is an orally active TAAR1-Gs/Gq agonist (EC50: 6.1/14.8 nM). ZH8965 improves antipsychotic-like phenotypes and cognitive impairment in the MK-801-induced mouse psychosis model. ZH8965 can be used in schizophrenia research.
    ZH8965
  • HY-176143
    P2Y1/P2Y6 antagonist 1 98%
    P2Y1/P2Y6 antagonist 1 (Compound 3h) is an indolesulfonylhydrazide derivative. P2Y1/P2Y6 antagonist 1 is an orally active tP2Y1 and rP2Y6 antagonist (IC50 of 9.72 and 1.89 μM, respectively). P2Y1/P2Y6 antagonist 1 can be used in the study of neurological diseases, inflammation, cardiovascular diseases and cancer.
    P2Y1/P2Y6 antagonist 1
  • HY-176146
    Keap1/Nrf2/ARE activator 1 98%
    Keap1/Nrf2/ARE activator 1 (compound HT-3) is a Keap1/Nrf2/ARE pathway activator. Keap1/Nrf2/ARE activator 1 exhibits antioxidant activity and neuroprotective efficacy.
    Keap1/Nrf2/ARE activator 1
  • HY-176200
    VU6008055 2170551-59-2
    VU6008055 is a potent, selective, cross the blood-brain barrier and orally actively M4 positive allosteric modulator with EC50 values of 73.4, 19.5 nM for hM4, rM4, respectively. VU6008055 shows antipsychotic-like activity.
    VU6008055
  • HY-176213
    JNK2/3-IN-1 98%
    JNK2/3-IN-1 (Compound 56d) is an irreversible covalent inhibitor of c-Jun N-terminal kinases 2/3 (JNK2/3) with IC50 values of 830 and 1909 nM, respectively. JNK2/3-IN-1 is promising for research of neurodegenerative diseases (e.g., Parkinson’s, Alzheimer’s) and fibrotic disorders.
    JNK2/3-IN-1
  • HY-176216
    5-HT2C agonist-5 3081797-69-2
    5-HT2C agonist-5 (Compound 3A) is a 5-HT2C agonist (EC50: <1 nM). 5-HT2C agonist-5 can be used for research of brain disorders.
    5-HT2C agonist-5
  • HY-176234
    PDE4-IN-28 98%
    PDE4-IN-28 (Compound G1) is a PDE4D inhibitor (IC50: 29 nM). PDE4-IN-28 inhibits the production of TNF-α and NO (IC50: 13.32 and 2.32 μM, respectively). PDE4-IN-28 exhibits anti-inflammatory, antibacterial and analgesic effects in a rat pressure ulcer (PU) model and promotes HUVEC cell migration, thereby accelerating wound healing.
    PDE4-IN-28
  • HY-176235
    PDE5-IN-14
    PDE5-IN-14 (Compound 14a) is a brain-penetrant competitive phosphodiesterase 5 (PDE5) inhibitor (IC50=16.11 nM). PDE5-IN-14 is promising for research of Alzheimer’s disease (AD), cancer and cardiovascular diseases.
    PDE5-IN-14
  • HY-17638A
    Mizagliflozin (sebacate) 1169392-27-1 98%
    Mizagliflozin sebacate (DSP-3235 sebacate) is a sodium-glucose cotransporter inhibitor with activity in improving vascular cognitive impairment caused by small vessel disease. Mizagliflozin sebacate improves blood flow and reverses vascular cognitive impairment by inhibiting neuronal SGLT1 activity. Mizagliflozin sebacate also showed the ability to increase the survival rate of IL-1β-treated PC12HS cells. Mizagliflozin sebacate promotes improvements in spatial learning and memory caused by small vessel disease in mouse models.
    Mizagliflozin (sebacate)
  • HY-176401
    AChE-IN-87 98%
    AChE-IN-87 (Compound 8j) is an AChE inhibitor (IC50: 0.05 μM; Ki: 16.93 nM). AChE-IN-87 is non-cytotoxic to 3T3 cells. AChE-IN-87 can be used in the study of Alzheimer's disease (AD).
    AChE-IN-87
  • HY-176402
    Dyrk1A-IN-13 98%
    Dyrk1A-IN-13 (Compound 1) is a DYRK1A inhibitor (IC50: 41 nM). Dyrk1A-IN-13 reduces LPS-induced NO production and has antioxidant and anti-inflammatory activities. Dyrk1A-IN-13 can be used in the research of Alzheimer's disease, cancer and diabetes.
    Dyrk1A-IN-13
  • HY-176405
    σ1R-IN-1 98%
    σ1R-IN-1 ((R,R)-1a) is a potent σ-1R inhibitor with an IC50 of 110 nM. σ1R-IN-1 is promising for research of neuropsychiatric disorders.
    σ1R-IN-1
  • HY-176409
    Phosphodiesterase-IN-4 98%
    Phosphodiesterase-IN-4 (compound 18) is a potent Tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor. Phosphodiesterase-IN-4 inhibits colorectal cancer cells with an IC50 of 6.9 μM.
    Phosphodiesterase-IN-4
Cat. No. Product Name / Synonyms Application Reactivity